Adocia to Present Clinical Data Validating BioChaperone® Technology at the 2016 EASD Annual Meeting

Presentations will feature encouraging data on the Company’s two lead programs: BioChaperone® Lispro in partnership with Eli Lilly, and BioChaperone® Combo

Lyon, France, September 8, 2016 – Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical stage biopharmaceutical company focused on diabetes treatment with innovative formulations of approved proteins, today announced that three abstracts reflecting promising data supporting the ongoing development of the company’s lead programs, BioChaperone® Lispro in partnership with Eli Lilly, and BioChaperone® Combo, have been accepted for publication and presentation at the 52nd European Association for the Study of Diabetes (EASD) Annual Meeting to be held September 12 – 16, 2016 in Munich, Germany.

Adocia and Eli Lilly will present data from a BioChaperone® Lispro study during the oral session "OP 02 Insulin Insights” on Tuesday, September 13, 2016 at 10:15 AM CET. Lead Scientist and Chairman of Profil Germany, Dr. Tim Heise, will present findings that demonstrate superior postprandial blood glucose control in patients with type 1 diabetes using ultra-rapid BioChaperone® Lispro vs. Humalog®.

During the same oral session, Dr. Simon Bruce, Adocia Chief Medical Officer, will present data from a euglycemic clamp study conducted in people with type 2 diabetes on BioChaperone® Combo that show a comparable prandial and basal effects compared to the double injection of Lantus® and Humalog® and improved prandial and basal effects vs. Humalog® Mix75/25™.

Later on September 13 between 12:00 PM - 01:00 PM CET, Adocia will present a poster discussing results from a meal tolerance test study in patients with type 1 diabetes demonstrating improved postprandial glycemic excursions and reduced risk of hypoglycemia of BioChaperone® Combo compared to Humalog® Mix75/25™.

Details of the abstracts on BioChaperone® Lispro and BioChaperone® Combo are outlined below:

**Oral Presentation: Ultra-Rapid BioChaperone® Lispro Ameliorates Postprandial Blood Glucose (PPG) Control Compared with Humalog in Subjects with Type 1 Diabetes Mellitus**

- **Submission Number:** A-16-1401-EASD
- **Presentation Number:** 07
- **Presenting Author:** Dr. Tim Heise
- **Session:** OP 02 Insulin Insights
- **Date and Time:** Tuesday September 13, 2016 10:15 AM - 11:45 AM CET
- **Location:** Langerhans Hall
Oral Presentation: BioChaperone® Combo, a co-formulation of lispro and glargine, demonstrates both prandial and basal insulin time-action profiles in a single injection in type 2 diabetes

Submission Number: A-16-1387-EASD
Presentation Number: 08
Presenting Author: Dr. Simon Bruce
Session: OP 02 Insulin Insights
Date and Time: Tuesday, September 13, 2016 10:15 AM - 11:45 AM CET
Location: Langerhans Hall

Poster Presentation: BioChaperone® Combo reduces post-prandial glucose in type 1 diabetes compared to conventional lispro mix 75/25 (LMx)

Submission Number: A-16-1363-EASD
Poster Number: 836
Session: PS 079 Insulin Therapy
Date and Time: Tuesday, September 13, 2016 12:00 PM - 01:00 PM CET
Location: Poster Hall

About the EASD Annual Meeting

The EASD Annual Meeting is one of the largest European medical meetings dedicated to the latest developments and insights in diabetes and diabetes therapies. The meeting attracts key opinion leaders, company executives, scientists, physicians, researchers, nurses and students interested in diabetes and related subjects. The goal of the EASD Annual Meeting is to encourage excellence in diabetes care through advances in research and education.

About ADOCIA

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. Adocia’s insulin formulation portfolio, featuring four clinical-stage products and one preclinical product, is among the largest and most differentiated in the industry.

The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application in order to address specific patient needs.

Adocia’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analogs (BioChaperone Lispro U100 and U200), a rapid-acting formulation of human insulin (HinsBet U100) and a combination of insulin glargine and a rapid-acting insulin analog (BioChaperone Combo). Adocia is also developing an aqueous formulation of human glucagon (BioChaperone Glucagon), combinations of insulin glargine with GLP-1s (BioChaperone Glargine Dulaglutide and BioChaperone Glargine Liraglutide) and a concentrated, rapid-acting formulation of human insulin (HinsBet U500), all of which are in preclinical development.

In December 2014, Adocia signed a partnership with Eli Lilly for the development and commercialization of the BioChaperone Lispro projects.

Adocia aims to deliver “Innovative medicine for everyone, everywhere.”

To learn more about Adocia, please visit us at www.adocia.com
For more information please contact:

<table>
<thead>
<tr>
<th>Adocia</th>
<th>Adocia Press Relations</th>
<th>Adocia Investor Relations USA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gérard Soula</td>
<td>Europe</td>
<td>The Ruth Group</td>
</tr>
<tr>
<td>Chairman and CEO</td>
<td>MC Services AG</td>
<td>Tram Bui</td>
</tr>
<tr>
<td><a href="mailto:contactinvestisseurs@adocia.com">contactinvestisseurs@adocia.com</a></td>
<td>Raimund Gabriel</td>
<td><a href="mailto:tbui@theruthgroup.com">tbui@theruthgroup.com</a></td>
</tr>
<tr>
<td>Tél. : +33 4 72 610 610</td>
<td><a href="mailto:adocia@mc-services.eu">adocia@mc-services.eu</a></td>
<td>Tel.: +646.536.7035</td>
</tr>
</tbody>
</table>

**Disclaimer**

This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 'Risk Factors' section of the Reference Document filed with the French Autorité des marchés financiers on April 8, 2016 (a copy of which is available on www.adocia.com) and to the development of economic conditions, financial markets and the markets in which Adocia operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not currently considered material by Adocia. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Adocia to be materially different from such forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia shares in any jurisdiction.